Expertise in
1
conditions

Dr. Valerie K. Arnold

Child and Adolescent Psychiatry | Psychiatry
1910 Nonconnah Blvd, Suite 120, 
Memphis, TN 
Accepting New Patients
Offers Telehealth
Expertise in
1
conditions
1910 Nonconnah Blvd, Suite 120, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Valerie Arnold is a Child and Adolescent Psychiatrist and a Psychiatrist in Memphis, Tennessee. Dr. Arnold is highly rated in 1 condition, according to our data. Her top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD) and Major Depression. Dr. Arnold is currently accepting new patients.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Child and Adolescent Psychiatry
Psychiatry
Licenses
Child & Adolescent Psychiatry in TN
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

1910 Nonconnah Blvd, Suite 120, Memphis, TN 38132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: September 08, 2025
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: April 06, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
Enrollment Status: Unknown
Publish Date: February 24, 2017
Intervention Type: Drug
Study Drug: NSI-189
Study Phase: Phase 2
View 8 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. Tejinder S. Saini
Psychiatry
Expertise in
13
conditions
Dr. Tejinder S. Saini
Psychiatry

Healthquest PC

58 Timber Creek Dr, 
Cordova, TN 
 (12.3 miles away)
901-308-2915
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Tejinder Saini is a Psychiatrist in Cordova, Tennessee. Dr. Saini is highly rated in 13 conditions, according to our data. His top areas of expertise are Bipolar Disorder (BPD), Major Depression, Schizophrenia, Advanced Bronchoscopy, and Colonoscopy. Dr. Saini is currently accepting new patients.

Expertise in
5
conditions
Dr. Ejaz S. Virk
Psychiatry
Expertise in
5
conditions
Dr. Ejaz S. Virk
Psychiatry
3000 Getwell Rd, 
Memphis, TN 
 (3.9 miles away)
901-672-6238
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ejaz Virk is a Psychiatrist in Memphis, Tennessee. Dr. Virk is highly rated in 5 conditions, according to our data. His top areas of expertise are Schizoaffective Disorder, Seasonal Affective Disorder (SAD), Major Depression, and Schizophrenia. Dr. Virk is currently accepting new patients.

Expertise in
8
conditions
Dr. Olayinka O. Akinwumiju
Psychiatry
Expertise in
8
conditions
Dr. Olayinka O. Akinwumiju
Psychiatry

Healthquest PC

8130 Country Village Dr, Suite 102, 
Cordova, TN 
 (13.3 miles away)
901-308-2915
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Olayinka Akinwumiju is a Psychiatrist in Cordova, Tennessee. Dr. Akinwumiju is highly rated in 8 conditions, according to our data. His top areas of expertise are Major Depression, Schizoaffective Disorder, Bipolar Disorder (BPD), and Seasonal Affective Disorder (SAD). Dr. Akinwumiju is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arnold's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile